Lars C. Wallentin
Duke University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Atrial Fibrillation Management and Outcomes
Strong evidence · 11 supporting papers · latest 2026
Cardiovascular Issues in Pregnancy
Solid evidence · 1 supporting paper · latest 2026
Venous Thromboembolism Diagnosis and Management
Solid evidence · 4 supporting papers · latest 2026
Antiplatelet Therapy and Cardiovascular Diseases
Solid evidence · 4 supporting papers · latest 2026
Genetic Associations and Epidemiology
Solid evidence · 1 supporting paper · latest 2026
Vitamin K Research Studies
Solid evidence · 3 supporting papers · latest 2026
Heart Failure Treatment and Management
Solid evidence · 2 supporting papers · latest 2026
Cardiac, Anesthesia and Surgical Outcomes
Solid evidence · 2 supporting papers · latest 2026
Publications (15)
DOAC score among patients receiving Vitamin K antagonists
2026DOIPMID 42336120
NT-proBNP in relation to clinical characteristics and cardiovascular outcomes in non-anticoagulated patients with atrial fibrillation
2026DOIPMID 42608180
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study
2026DOIPMID 42043183
Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation
2026DOIPMID 42187550
Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis
2026DOIPMID 42549517
Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation
2026DOIPMID 42489381
Major adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of a large cohort of patients from the COMBINE-AF
2026DOIPMID 41714252
Pregnancy in Women With Impaired Left Ventricular Function
2026DOIPMID 41747706
Response by Oldgren and Wallentin to Letter Regarding Article, “Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study”
2026DOIPMID 42766685
Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF
2026DOIPMID 42059513
Outcomes With Warfarin in Atrial Fibrillation
2026DOIPMID 42489390
Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome
2026DOIPMID 42097137
26-A-14153-ACC INR RARELY >1.5 IN PATIENTS ON APIXABAN: RESULTS FROM THE ARISTOTLE TRIAL
2026DOI
26-A-9790-ACC PREDICTORS OF GASTROINTESTINAL BLEEDING IN ATRIAL FIBRILLATION: A PATIENT-LEVEL POOLED ANALYSIS OF LARGE-SCALE RANDOMIZED TRIALS FROM COMBINE AF
2026DOI
Abstract Wed030: Extra-Large HDL Particles and Cardiovascular Events in a High-Risk Cohort
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Duke University
Source: OpenAlex · retrieved 2026-09-29